Early Detection and Diagnosis

You have full text access to this OnlineOpen article

Identification of novel DNA methylation markers in cervical cancer†

  1. Hung-Cheng Lai1,2,‡,*,
  2. Ya-Wen Lin2,3,
  3. Tim H.M. Huang4,
  4. Pearlly Yan4,
  5. Rui-Lan Huang1,
  6. Hui-Chen Wang1,
  7. Joseph Liu4,
  8. Michael W.Y. Chan5,
  9. Tang-Yuan Chu6,
  10. Chien-An Sun7,
  11. Cheng-Chang Chang1,
  12. Mu-Hsien Yu1

Article first published online: 8 APR 2008

DOI: 10.1002/ijc.23519

Issue

International Journal of Cancer

International Journal of Cancer

Volume 123, Issue 1, pages 161–167, 1 July 2008

Additional Information

How to Cite

Lai, H.-C., Lin, Y.-W., Huang, T. H.M., Yan, P., Huang, R.-L., Wang, H.-C., Liu, J., Chan, M. W.Y., Chu, T.-Y., Sun, C.-A., Chang, C.-C. and Yu, M.-H. (2008), Identification of novel DNA methylation markers in cervical cancer. Int. J. Cancer, 123: 161–167. doi: 10.1002/ijc.23519

Author Information

  1. 1

    Department of Obstetrics and Gynecology, Tri-Service General Hospital, Taipei, Taiwan, Republic of China

  2. 2

    Laboratory of Epigenetics, National Defense Medical Center, Taipei, Taiwan, Republic of China

  3. 3

    Department of Microbiology and Immunology, National Defense Medical Center, Taipei, Taiwan, Republic of China

  4. 4

    Human Cancer Genetics Program, Department of Molecular Virology, Immunology and Medical Genetics, Comprehensive Cancer Center, Ohio State University, Columbus, OH

  5. 5

    Department of Life Science, National Chung Cheng University, Min-Hsiung Chia-Yi, Taiwan, Republic of China

  6. 6

    Department of Obstetrics and Gynecology, Buddhist Tzu Chi General Hospital, Tzu Chi University, Hualien, Taiwan, Republic of China

  7. 7

    School of Public Health, National Defense Medical Center, Taipei, Taiwan, Republic of China

  1. ‡

    Fax: +886-2-8792-7199.

*Department of Obstetrics and Gynecology, Tri-Service General Hospital, National Defense Medical Center, 5F, 325, Sec 2, Cheng-Gong Rd., Neihu District, Taipei City 114, Taiwan, Republic of China

  1. †

    The application for patents using these DNA sequences in cancer screening is in processing.

Publication History

  1. Issue published online: 24 APR 2008
  2. Article first published online: 8 APR 2008
  3. Manuscript Accepted: 23 JAN 2008
  4. Manuscript Received: 19 JAN 2008

Funded by

  • Tri-Service General Hospital. Grant Number: TSGH-C96-2-S01∼4
  • National Science Council, Republic of China. Grant Numbers: NSC95-2622-B-016-001, NSC95-2314-B-016-058-MY2
  • C.Y. Chai Foundation for Advancement of Education, Sciences and Medicine
  • Human Medical Research Foundation. Grant Number: B962114-1

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article with Supporting Information (HTML) Get PDF (387K)

References

  • 1
    Feinberg AP,Tycko B. The history of cancer epigenetics. Nat Rev Cancer 2004; 4: 143–53.
  • 2
    Jones PA,Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002; 3: 415–28.
  • 3
    Laird PW. The power and the promise of DNA methylation markers. Nat Rev Cancer 2003; 3: 253–66.
  • 4
    Bird AP. CpG-rich islands and the function of DNA methylation. Nature 1986; 321: 209–13.
  • 5
    Larsen F,Gundersen G,Lopez R,Prydz H. CpG islands as gene markers in the human genome. Genomics 1992; 13: 1095–107.
  • 6
    Robertson KD. DNA methylation and chromatin—unraveling the tangled web. Oncogene 2002; 21: 5361–79.
  • 7
    Baylin SB,Herman JG. DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet 2000; 16: 168–74.
  • 8
    Jones PA,Laird PW. Cancer epigenetics comes of age. Nat Genet 1999; 21: 163–7.
  • 9
    Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol 2001; 2: 533–43.
  • 10
    Walboomers JM,Jacobs MV,Manos MM,Bosch FX,Kummer JA,Shah KV,Snijders PJ,Peto J,Meijer CJ,Munoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189: 12–19.
    Direct Link:
  • 11
    zur Hausen H. Cervical carcinoma and human papillomavirus: on the road to preventing a major human cancer. J Natl Cancer Inst 2001; 93: 252–3.
  • 12
    Sova P,Feng Q,Geiss G,Wood T,Strauss R,Rudolf V,Lieber A,Kiviat N. Discovery of novel methylation biomarkers in cervical carcinoma by global demethylation and microarray analysis. Cancer Epidemiol Biomarkers Prev 2006; 15: 114–23.
  • 13
    Feng Q,Balasubramanian A,Hawes SE,Toure P,Sow PS,Dem A,Dembele B,Critchlow CW,Xi L,Lu H,McIntosh MW,Young AM, et al. Detection of hypermethylated genes in women with and without cervical neoplasia. J Natl Cancer Inst 2005; 97: 273–82.
  • 14
    Steenbergen RD,Kramer D,Braakhuis BJ,Stern PL,Verheijen RH,Meijer CJ,Snijders PJ. TSLC1 gene silencing in cervical cancer cell lines and cervical neoplasia. J Natl Cancer Inst 2004; 96: 294–305.
  • 15
    Narayan G,Arias-Pulido H,Koul S,Vargas H,Zhang FF,Villella J,Schneider A,Terry MB,Mansukhani M,Murty VV. Frequent promoter methylation of CDH1, DAPK, RARB, and HIC1 genes in carcinoma of cervix uteri: its relationship to clinical outcome. Mol Cancer 2003; 2: 24.
  • 16
    Lai HC,Lin YW,Chang CC,Wang HC,Chu TW,Yu MH,Chu TY. Hypermethylation of two consecutive tumor suppressor genes, BLU and RASSF1A, located at 3p21.3 in cervical neoplasias. Gynecol Oncol 2006; 104: 629–35.
  • 17
    Widschwendter A,Gattringer C,Ivarsson L,Fiegl H,Schneitter A,Ramoni A,Muller HM,Wiedemair A,Jerabek S,Muller-Holzner E,Goebel G,Marth C, et al. Analysis of aberrant DNA methylation and human papillomavirus DNA in cervicovaginal specimens to detect invasive cervical cancer and its precursors. Clin Cancer Res 2004; 10: 3396–400.
  • 18
    Chu TY,Hwang KS,Yu MH,Lee HS,Lai HC,Liu JY. A research-based tumor tissue bank of gynecologic oncology: characteristics of nucleic acids extracted from normal and tumor tissues from different sites. Int J Gynecol Cancer 2002; 12: 171–6.
    Direct Link:
  • 19
    Yan PS,Perry MR,Laux DE,Asare AL,Caldwell CW,Huang TH. CpG island arrays: an application toward deciphering epigenetic signatures of breast cancer. Clin Cancer Res 2000; 6: 1432–8.
  • 20
    Gravitt PE,Peyton CL,Apple RJ,Wheeler CM. Genotyping of 27 human papillomavirus types by using L1 consensus PCR products by a single-hybridization, reverse line blot detection method. J Clin Microbiol 1998; 36: 3020–7.
  • 21
    Lai HC,Chang CC,Lin YW,Chen SF,Yu MH,Nieh S,Chu TW,Chu TY. Genetic polymorphism of the interferon-gamma gene in cervical carcinogenesis. Int J Cancer 2005; 113: 712–18.
    Direct Link:
  • 22
    Leu YW,Yan PS,Fan M,Jin VX,Liu JC,Curran EM,Welshons WV,Wei SH,Davuluri RV,Plass C,Nephew KP,Huang TH. Loss of estrogen receptor signaling triggers epigenetic silencing of downstream targets in breast cancer. Cancer Res 2004; 64: 8184–92.
  • 23
    Rahmatpanah FB,Carstens S,Guo J,Sjahputera O,Taylor KH,Duff D,Shi H,Davis JW,Hooshmand SI,Chitma-Matsiga R,Caldwell CW. Differential DNA methylation patterns of small B-cell lymphoma subclasses with different clinical behavior. Leukemia 2006; 20: 1855–62.
  • 24
    Ekonomou A,Kazanis I,Malas S,Wood H,Alifragis P,Denaxa M,Karagogeos D,Constanti A,Lovell-Badge R,Episkopou V. Neuronal migration and ventral subtype identity in the telencephalon depend on SOX1. PLoS Biol 2005; 3: e186.
  • 25
    Wilm B,Dahl E,Peters H,Balling R,Imai K. Targeted disruption of Pax1 defines its null phenotype and proves haploinsufficiency. Proc Natl Acad Sci USA 1998; 95: 8692–7.
  • 26
    Chizhikov VV,Millen KJ. Control of roof plate formation by Lmx1a in the developing spinal cord. Development 2004; 131: 2693–705.
  • 27
    Sander M,Sussel L,Conners J,Scheel D,Kalamaras J,Dela Cruz F,Schwitzgebel V,Hayes-Jordan A,German M. Homeobox gene Nkx6.1 lies downstream of Nkx2.2 in the major pathway of beta-cell formation in the pancreas. Development 2000; 127: 5533–40.
  • 28
    Roberts SG. Transcriptional regulation by WT1 in development. Curr Opin Genet Dev 2005; 15: 542–7.
  • 29
    Robson EJ,He SJ,Eccles MR. A PANorama of PAX genes in cancer and development. Nat Rev Cancer 2006; 6: 52–62.
  • 30
    Odom DT,Zizlsperger N,Gordon DB,Bell GW,Rinaldi NJ,Murray HL,Volkert TL,Schreiber J,Rolfe PA,Gifford DK,Fraenkel E,Bell GI, et al. Control of pancreas and liver gene expression by HNF transcription factors. Science 2004; 303: 1378–81.
  • 31
    Fukuda H,Takahashi J,Watanabe K,Hayashi H,Morizane A,Koyanagi M,Sasai Y,Hashimoto N. Fluorescence-activated cell sorting-based purification of embryonic stem cell-derived neural precursors averts tumor formation after transplantation. Stem Cells 2006; 24: 763–71.
    Direct Link:
  • 32
    Paz MF,Wei S,Cigudosa JC,Rodriguez-Perales S,Peinado MA,Huang TH-M,Esteller M. Genetic unmasking of epigenetically silenced tumor suppressor genes in colon cancer cells deficient in DNA methyltransferases. Hum Mol Genet 2003; 12: 2209–19.
  • 33
    Nakatsuka S,Oji Y,Horiuchi T,Kanda T,Kitagawa M,Takeuchi T,Kawano K,Kuwae Y,Yamauchi A,Okumura M,Kitamura Y,Oka Y, et al. Immunohistochemical detection of WT1 protein in a variety of cancer cells. Mod Pathol 2006; 19: 804–14.
  • 34
    Lazarevich NL,Cheremnova OA,Varga EV,Ovchinnikov DA,Kudrjavtseva EI,Morozova OV,Fleishman DI,Engelhardt NV,Duncan SA. Progression of HCC in mice is associated with a downregulation in the expression of hepatocyte nuclear factors. Hepatology 2004; 39: 1038–47.
    Direct Link:
  • 35
    Mahlck CG,Jonsson H,Lenner P. Pap smear screening and changes in cervical cancer mortality in Sweden. Int J Gynaecol Obstet 1994; 44: 267–72.
  • 36
    Liu S,Semenciw R,Probert A,Mao Y. Cervical cancer in Canada: changing patterns in incidence and mortality. Int J Gynecol Cancer 2001; 11: 24–31.
    Direct Link:
  • 37
    Anttila A,Pukkala E,Soderman B,Kallio M,Nieminen P,Hakama M. Effect of organised screening on cervical cancer incidence and mortality in Finland, 1963–1995: recent increase in cervical cancer incidence. Int J Cancer 1999; 83: 59–65.
    Direct Link:
  • 38
    Cuzick J,Szarewski A,Cubie H,Hulman G,Kitchener H,Luesley D,McGoogan E,Menon U,Terry G,Edwards R,Brooks C,Desai M, et al. Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet 2003; 362: 1871–6.
  • 39
    Franco EL,Cuzick J,Hildesheim A,De Sanjose S. Chapter 20: issues in planning cervical cancer screening in the era of HPV vaccination. Vaccine 2006; 24 ( Suppl 3): S171–7.
  • 40
    Snijders PJ,Hogewoning CJ,Hesselink AT,Berkhof J,Voorhorst FJ,Bleeker MC,Meijer CJ. Determination of viral load thresholds in cervical scrapings to rule out CIN 3 in HPV 16, 18, 31 and 33-positive women with normal cytology. Int J Cancer 2006; 119: 1102–7.
    Direct Link:
  • 41
    Molden T,Nygard JF,Kraus I,Karlsen F,Nygard M,Skare GB,Skomedal H,Thoresen SO,Hagmar B. Predicting CIN2+ when detecting HPV mRNA and DNA by PreTect HPV-proofer and consensus PCR: A 2-year follow-up of women with ASCUS or LSIL Pap smear. Int J Cancer 2005; 114: 973–6.
    Direct Link:
  • 42
    Ekalaksananan T,Pientong C,Sriamporn S,Kongyingyoes B,Pengsa P,Kleebkaow P,Kritpetcharat O,Parkin DM. Usefulness of combining testing for p16 protein and human papillomavirus (HPV) in cervical carcinoma screening. Gynecol Oncol 2006; 103: 62–6.
  • 43
    Franco EL,Ferenczy A. Is HPV testing with cytological triage a more logical approach in cervical cancer screening? Lancet Oncol 2006; 7: 527–9.
  • 44
    Brink AA,Meijer CJ,Wiegerinck MA,Nieboer TE,Kruitwagen RF,van Kemenade F,Fransen Daalmeijer N,Hesselink AT,Berkhof J,Snijders PJ. High concordance of results of testing for human papillomavirus in cervicovaginal samples collected by two methods, with comparison of a novel self-sampling device to a conventional endocervical brush. J Clin Microbiol 2006; 44: 2518–23.
  • 45
    Kagan J,Srivastava S,Barker PE,Belinsky SA,Cairns P. Towards clinical application of methylated DNA sequences as cancer biomarkers: a joint NCI's EDRN and NIST workshop on standards, methods, assays, reagents and tools. Cancer Res 2007; 67: 4545–9.
  • 46
    Bulkmans NW,Rozendaal L,Snijders PJ,Voorhorst FJ,Boeke AJ,Zandwijken GR,van Kemenade FJ,Verheijen RH,v Groningen K,Boon ME,Keuning HJ,van Ballegooijen M, et al. POBASCAM, a population-based randomized controlled trial for implementation of high-risk HPV testing in cervical screening: design, methods and baseline data of 44,102 women. Int J Cancer 2004; 110: 94–101.
    Direct Link:
  • 47
    Kitchener HC,Almonte M,Wheeler P,Desai M,Gilham C,Bailey A,Sargent A,Peto J. HPV testing in routine cervical screening: cross sectional data from the ARTISTIC trial. Br J Cancer 2006; 95: 56–61.
  • 48
    Mayrand MH,Duarte-Franco E,Coutlee F,Rodrigues I,Walter SD,Ratnam S,Franco EL. Randomized controlled trial of human papillomavirus testing versus Pap cytology in the primary screening for cervical cancer precursors: design, methods and preliminary accrual results of the Canadian cervical cancer screening trial (CCCaST). Int J Cancer 2006; 119: 615–23.
    Direct Link:
View Full Article with Supporting Information (HTML) Get PDF (387K)